Page last updated: 2024-09-04

olmesartan and terazosin

olmesartan has been researched along with terazosin in 2 studies

Compound Research Comparison

Studies (olmesartan)	Trials (olmesartan)	Recent Studies (post-2010) (olmesartan)	Studies (terazosin)	Trials (terazosin)	Recent Studies (post-2010) (terazosin)
841	185	554	658	173	104

Protein Interaction Comparison

Protein	Taxonomy	terazosin (IC50)
Alpha-2B adrenergic receptor	Homo sapiens (human)	0.428
Alpha-2C adrenergic receptor	Homo sapiens (human)	6.042
Alpha-1D adrenergic receptor	Homo sapiens (human)	0.011
Alpha-1A adrenergic receptor	Homo sapiens (human)	0.005
Alpha-1B adrenergic receptor	Homo sapiens (human)	0.005

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY	1
Gandhi, HP; Giridhar, R; Naik, PP; Yadav, MR	1

Other Studies

2 other study(ies) available for olmesartan and terazosin

Article	Year
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding	2012
Revelation on the potency of α(1) -blockers - parallel blockade of angiotensin II receptor: a new finding. Pharmaceutical biology, 2012, Volume: 50, Issue:4 Topics: Adrenergic alpha-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta, Thoracic; Dose-Response Relationship, Drug; Doxazosin; Imidazoles; In Vitro Techniques; Losartan; Male; Molecular Structure; Prazosin; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptors, Adrenergic, alpha-1; Structure-Activity Relationship; Tetrazoles; Valine; Valsartan; Vasodilation; Vasodilator Agents	2012

Article

Year

Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.

Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012

Revelation on the potency of α(1) -blockers - parallel blockade of angiotensin II receptor: a new finding.

Pharmaceutical biology, 2012, Volume: 50, Issue:4

Topics: Adrenergic alpha-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta, Thoracic; Dose-Response Relationship, Drug; Doxazosin; Imidazoles; In Vitro Techniques; Losartan; Male; Molecular Structure; Prazosin; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptors, Adrenergic, alpha-1; Structure-Activity Relationship; Tetrazoles; Valine; Valsartan; Vasodilation; Vasodilator Agents

2012